The Risk of Acute Myeloid Leukaemia in Patients With Ewing's Sarcoma

NCT06659224 | Completed

• 1 other identifier: A275
• Study Type: observational
• Target: 2,631
• Locations: 1 country
• Sites: 1

Brief Summary

Ewing's sarcoma is an uncommon yet vital malignancy of bone. It demonstrates a predilection for the pediatric and young adult population. Chemotherapy is considered an important treatment modality for Ewing's sarcoma. However, the development of therapy-related leukemia, especially acute myeloid leukemia following treatment, is attributed to the use of substances such as alkylating agents and topoisomerase inhibitors which are genotoxic. There is a very few studies elaborating on the incidence rates of such complications. So, our aim is to quantify the risk of developing acute myeloid leukemia in Ewing sarcoma patients and provide an updated evidence to the literature.

Conditions

Acute Myeloid Leukemia (AML); Ewing Sarcoma

Keywords

acute myeloid leukemia; Ewing sarcoma; SEER

Outcome Measures

Primary Outcomes (1)

• The standardized incidence ratio and excess risk of developing acute myeloid leukemia in Ewing's sarcoma patients

  The surveillance, epidemiology and End Results (SEER) database was used to calculate the standardized incidence ratio (SIR) as Observed/Expected (O/E) and calculated the excess absolute risk for acute myeloid leukemia in Ewing's sarcoma patients.

  from Jan, 2000 till Dec, 2021

Secondary Outcomes (2)

• The standardized incidence ratio and excess risk of second primary malignancies in Ewing's sarcoma patients across different racial groups

  from Jan, 2000 till Dec, 2021

• The standardized incidence ratio and excess risk of second primary malignancies in Ewing's sarcoma patients between different stages

  from Jan, 2000 till Dec, 2021

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients diagnosed with Ewing sarcoma between 2000 and 2021, followed up for more than 10 years after the initial diagnosis. Site record ICD-O-3/WHO 2008 restricted to bone and soft tissue; and histological type ICD-O-3 specified as Ewing sarcoma (9364)

You may qualify if:

• Patients diagnosed with Ewing sarcoma
• Sequence 0 or 1

You may not qualify if:

• patients lacking age documentation or age reported only on death certificates or autopsies

Sponsors & Collaborators

• asmaa salama ibrahim: lead

Study Sites (1)

Suez Canal University

Ismailia, 41512, Egypt

Location

MeSH Terms

Conditions

Leukemia, Myeloid, Acute; Sarcoma, Ewing

Condition Hierarchy (Ancestors)

Leukemia, Myeloid; Leukemia; Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases; Osteosarcoma; Neoplasms, Bone Tissue; Neoplasms, Connective Tissue; Neoplasms, Connective and Soft Tissue; Sarcoma

Study Officials

• Asmaa Ellaithy, MD

  Suez Canal University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Resident physician of gastroenterology

Study Record Dates

• First Submitted: October 23, 2024
• First Posted: October 26, 2024
• Study Start: January 1, 2000
• Primary Completion: December 30, 2021
• Study Completion: December 30, 2021
• Last Updated: July 23, 2025

Record last verified: 2025-07

Locations

EG (1)